ZORYVE
Jul 19, 2024
ZORYVE for Atopic Dermatitis Treatment: Is the Breakthrough We’ve Been Waiting for?
After a few days of investor anxiety, Arcutis Biotherapeutics announced that the FDA has approved ZORYVE for a new indication: atopic dermatitis. The FDA was scheduled to announce its decision on ZORYVE (roflumilast) for this new use on the 7th of this month, but the date passed without news. In an uncommon move to...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
